PMID- 34295558
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 2078-6891 (Print)
IS  - 2219-679X (Electronic)
IS  - 2078-6891 (Linking)
VI  - 12
IP  - 3
DP  - 2021 Jun
TI  - TSC1/2 mutations-a unique type of mutation suitable for liver transplantation of 
      Hepatocellular carcinoma.
PG  - 1074-1085
LID - 10.21037/jgo-20-378 [doi]
AB  - BACKGROUND: This study aimed to investigate the relationship between the 
      prognosis of patients with hepatocellular carcinoma (HCC) after liver 
      transplantation and mammalian target of rapamycin (mTOR) pathway-related 
      genes-TSC1/2. METHODS: We retrospectively analyzed the clinical data of 46 
      patients who underwent liver transplantation for HCC and performed next 
      generation sequencing to analyze the relationship between the efficacy of 
      sirolimus after liver transplantation for HCC and mutations in mTOR 
      pathway-related genes, especially tuberous sclerosis complex (TSC) mutations. 
      RESULTS: The average age of 46 patients with liver transplantation for HCC was 
      51+/-21 years. After surgery, 35 patients received an anti-rejection/anti-tumor 
      regimen that included sirolimus, and 11 patients did not receive sirolimus. There 
      was no significant difference in survival rate between the two groups (P=0.761). 
      The gene sequencing results showed mTOR-related pathway mutations in 10 patients, 
      of whom five (10.9%) had TSC1/2 mutations. Of the 35 patients using sirolimus, 
      those with mTOR-related mutations had significantly better survival rates than 
      patients without mTOR-related mutations (P=0.016). CONCLUSIONS: According to 
      genetic sequencing results, a personalized treatment plan for specific genetic 
      mutations should be selected in patients undergoing liver transplantation for 
      HCC. Patients with mTOR-related gene mutations, especially TSC mutations, can 
      gain significant benefits from the use of mTOR inhibitors such as sirolimus.
CI  - 2021 Journal of Gastrointestinal Oncology. All rights reserved.
FAU - Wei, Jinming
AU  - Wei J
AD  - Guangdong Provincial Key Laboratory of Liver Disease Research, Guangzhou, China.
FAU - Ye, Linsen
AU  - Ye L
AD  - Guangdong Provincial Key Laboratory of Liver Disease Research, Guangzhou, China.
FAU - Song, Laien
AU  - Song L
AD  - Guangdong Provincial Key Laboratory of Liver Disease Research, Guangzhou, China.
FAU - Tang, Hui
AU  - Tang H
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Zhang, Tong
AU  - Zhang T
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Fu, Binsheng
AU  - Fu B
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Zhang, Yingcai
AU  - Zhang Y
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Yang, Qing
AU  - Yang Q
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
FAU - Yi, Shuhong
AU  - Yi S
AD  - Department of Hepatic Surgery and Liver Transplantation Center, The Third 
      Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - J Gastrointest Oncol
JT  - Journal of gastrointestinal oncology
JID - 101557751
PMC - PMC8261316
OTO - NOTNLM
OT  - Hepatocellular carcinoma (HCC)
OT  - TSC gene mutation
OT  - liver transplantation
OT  - survival prognosis
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/jgo-20-378). The authors have no 
      conflicts of interest to declare.
EDAT- 2021/07/24 06:00
MHDA- 2021/07/24 06:01
PMCR- 2021/06/01
CRDT- 2021/07/23 06:49
PHST- 2020/09/08 00:00 [received]
PHST- 2021/04/07 00:00 [accepted]
PHST- 2021/07/23 06:49 [entrez]
PHST- 2021/07/24 06:00 [pubmed]
PHST- 2021/07/24 06:01 [medline]
PHST- 2021/06/01 00:00 [pmc-release]
AID - jgo-12-03-1074 [pii]
AID - 10.21037/jgo-20-378 [doi]
PST - ppublish
SO  - J Gastrointest Oncol. 2021 Jun;12(3):1074-1085. doi: 10.21037/jgo-20-378.